On June 26th, Globenewswire reported that Amoy Diagnostics (300685.SZ) recently signed a companion diagnostic cooperation agreement (hereinafter referred to as the 'Agreement') with LES LABORATOIRES SERVIER (hereinafter referred to as 'Servier'). The company's independently developed second-generation sequencing (NGS) platform's companion diagnostic product is used to detect isocitrate dehydrogenase (IDH) 1 and 2 gene mutations. This companion diagnostic product will be used in Servier's investigational drug, Vorasidenib, a dual inhibitor of IDH1 and IDH2 mutations, and is expected to be used to treat Chinese patients with diffuse glioma (LGG) carrying IDH mutations after approval.
According to reports, Servier is an international group managed by a foundation that aims to serve human health and hopes to bring profound social impact to patients and sustainable development of the world. With its unique management model, Servier fully implements its long-term mission with a developmental vision: dedicated to promoting progress in the treatment field and serving patient needs.
The announcement states that empowering original drug clinical trials with companion diagnostics and promoting more and better treatment methods to serve patients is the company's clear global strategy. The company's circle of pharmaceutical friends continues to expand, and collaboration fields and regions continue to expand. From TKIs targeted drugs, PARPi drugs, to immunotherapy drugs, ADC drugs, etc., all have realized the forward-looking layout of companion diagnostic products, grasping the innovation source of future markets. The companion diagnostic cooperation reached with Servier this time is beneficial to further enhance the company's competitiveness in the tumor precision medicine market and will have a positive impact on the company's future development.